Jaguar Health has bolstered its financial position with a $3 million payment received this Tuesday from its licensing partner, Future Pak. This capital infusion stems from the elimination of a buy-back provision within the companies’ existing U.S. licensing agreement. Concurrently, the company is implementing a special dividend initiative designed to protect existing shareholders as it navigates a period of debt restructuring.
Shareholder Safeguard Through Special Dividend
A key parallel action by management focuses on stabilizing the capital structure. The record date for a one-time special dividend, issued in the form of Series O convertible preferred shares, was set for Monday. Eligible common stockholders and warrant holders will see these shares deposited into their accounts on Wednesday, March 4.
According to CEO Lisa Conte, this distribution acts primarily as a protective mechanism for current investors. The measure is intended to limit potential share dilution while the company actively works on restructuring its liabilities.
Expanded Partnership Drives Multi-Million Dollar Inflows
The recent $3 million payment adds to a broader licensing partnership originally established in January 2026. This agreement grants Future Pak exclusive U.S. commercialization rights for Mytesi, used in treating HIV-associated diarrhea, and for Canalevia-CA1, which has veterinary applications.
Should investors sell immediately? Or is it worth buying Jaguar Health?
To date, this collaboration has provided Jaguar Health with a total of $16 million in non-dilutive capital. An additional $2 million remains contingent upon meeting specific conditions. The contract also outlines potential future milestone payments of up to $20 million, which would be triggered upon achieving certain development or commercial sales targets.
Strategic Pivot to Rare Disease Therapeutics
The funds generated through this partnership are being channeled into a strategic refocusing of Jaguar Health’s clinical research efforts. Resources are now being directed toward developing the drug candidate crofelemer for treating rare intestinal disorders.
The company is targeting conditions such as Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF). Previous study data from Abu Dhabi supports this approach, showing that MVID patients experienced a reduction in dependence on parenteral nutrition by up to 27%.
Building on these results, Jaguar Health is pursuing Breakthrough Therapy designation for crofelemer in this indication. The development timeline aims for a New Drug Application (NDA) submission for MVID in the first half of 2027.
Ad
Jaguar Health Stock: Buy or Sell?! New Jaguar Health Analysis from March 4 delivers the answer:
The latest Jaguar Health figures speak for themselves: Urgent action needed for Jaguar Health investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 4.
Jaguar Health: Buy or sell? Read more here...
